Jake Adler was running a biotech company out of his parents' garage. He was 20 years old.
Now 21, Adler has secured $25 million in seed funding for Pilgrim, his Redwood City-based defense biotechnology firm, the company disclosed this week in an interview with the Wall Street Journal. Buckley Ventures led the round, which valued the three-year-old startup at roughly $150 million, according to the Journal. The company would not clarify whether that figure applies before or after the investment.
The funding attracted a peculiar cross-section of Silicon Valley power. Peter Thiel invested in a personal capacity, as did Coinbase co-founders Brian Armstrong and Fred Ehrsam. Two technical researchers from Anthropic, the AI safety lab, also joined: Logan Graham, who runs the company's frontier red-team operations, and Sholto Douglas. Institutional money came from Thiel Capital, Cantos, Conviction, Shine Capital, Mantis, Refactor Capital, and Magellan, per Pilgrim's website.
Adler wrote on LinkedIn that the raise brings total capital to more than $30 million since Pilgrim's 2023 launch.
Building a biology prime
Pilgrim calls itself "America's first biology prime," a reference to the defense industry's traditional prime contractors. The company manufactures three hardware systems: ARGUS, an autonomous biosurveillance device; KINGSFOIL, a battlefield dressing for hemorrhage control; and BIFROST, cold-chain equipment designed to preserve medical supplies in hostile territory.
ARGUS is the flagship product. The 50-pound system pulls air samples at 325 liters per minute, then sequences genetic material on-device to identify pathogens. According to the Journal's Tech News Briefing podcast, it can detect threats like Ebola and anthrax in under 60 minutes. The unit combines UV laser-induced fluorescence with quantitative PCR and sequencing, powered by 157 TOPS of onboard compute.
Pilgrim says it has signed an agreement with the CDC for biosurveillance deployment, though the company has not provided documentation and no independent CDC statement naming the company has surfaced publicly. Adler noted on LinkedIn that initial deployments are already happening.
The youngest in the room
Adler graduated high school in 2022, according to his personal website. A year later, he received a Thiel Fellowship, the program that pays young founders $100,000 to skip college and build companies instead. He describes his background as hardware engineering and chemistry.
In a September interview with Axios, Adler framed Pilgrim's mission in stark terms. The company, he said, is working to create "a new generation of military medicine." Then he added: "You can't have a force multiplier without the underlying force."
Until recently, Pilgrim operated from a residential garage. Earlier this year it reportedly moved into a 20,000-square-foot facility in Redwood City, according to updates on the company's site. LinkedIn lists between two and 10 employees, with 11 individual profiles visible as of late September. The company is now hiring molecular biologists, electrical and mechanical engineers, and government-operations personnel.
A moment for defense tech
The timing is favorable. Defense technology venture funding has accelerated sharply. PitchBook data cited by ClearanceJobs in August showed that investors committed $35.6 billion to defense and defense-adjacent startups in the first half of this year, with median round sizes jumping from $11 million to $20 million year-over-year.
Pilgrim enters a biosurveillance market already occupied by established players. Thermo Fisher Scientific offers its AerosolSense platform. BioFlyte produces aerosol detection systems. The CDC itself runs a Traveler-Based Genomic Surveillance program that surpassed one million participants in January, per a CDC news release, signaling robust government appetite for early pathogen-detection infrastructure.
As of September, Pilgrim had no active Department of Defense contracts, Axios reported at the time. The startup was in conversations with the Defense Threat Reduction Agency, the Defense Health Agency, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Whether those discussions have advanced to formal contracts has not been publicly confirmed.
Why the Anthropic angle matters
Graham's investment came with a public explanation. Writing on X, he described "building a bio-shield for humanity by ~2030" as "one of the great quests," adding that this vision motivated his personal stake in Pilgrim. Anthropic has published research on biological misuse risks and AI-enabled biological threats, though the lab has offered no institutional comment on the Pilgrim round.
The involvement of Anthropic researchers in a defense biotech deal is notable, if only because it illustrates how porous the boundaries between AI safety and national security have become. Graham and Douglas are technical staff, not executives, but their participation suggests a cohort of AI researchers thinking beyond model weights and toward harder-edged applications.
Pilgrim's trajectory raises familiar questions about the defense startup playbook: Can a garage operation scale to meet Pentagon procurement timelines? Will a 21-year-old founder navigate the bureaucratic labyrinth of federal contracting? And perhaps most pressing, can biosurveillance hardware prove itself in the field before the next outbreak demands it?
For now, the company has capital and credibility. Whether it can deliver on both remains the open question.
